B6;129S-Cert1tm1Jsau/Cnbc

Status

Available to order

EMMA IDEM:08304
Citation informationRRID:IMSR_EM:08304 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameB6;129S-Cert1tm1Jsau/Cnbc
Alternative nameKin-LoxPe11-GPBP-1
Strain typeTargeted Mutant Strains : Conditional mutation
Allele/Transgene symbolCert1tm1Jsau
Gene/Transgene symbolCert1

Information from provider

ProviderJuan Bautista Saus Mas
Provider affiliationBioquímica y Biología Molecular., Universidad de Valencia. Facultad de Medicina.
Genetic informationTargeted insertion of a loxP site between exons 10 and 11 as well as a floxed neomycin resistance cassette between exons 11 and 12. The loxP site between exons 10 and 11 was inserted using a PCR strategy.
Phenotypic informationHomozygous:
There is no evident phenotype in this strain.

Heterozygous:
There is no evident phenotype in this strain.
Breeding historyTo generate floxed Cert1 (GPBP-1) mice, previously obtained (neo+/loxP+) 129/SvEv ES cells transfected with a suitable replacement vector, were injected into C57BL/6 blastocysts. The resulting chimeric mice were further crossed to obtain homozygous (neo+/loxP+) mice. Later they were backcrossed to C57BL/6 and maintained during several years. There is no specific information about the number of generations backcrossed and sib-mated.
References
  • Goodpasture antigen-binding protein (GPBP) directs myofibril formation: identification of intracellular downstream effector 130-kDa GPBP-interacting protein (GIP130).;Revert-Ros Francisco, López-Pascual Ernesto, Granero-Moltó Froilán, Macías Jesús, Breyer Richard, Zent Roy, Hudson Billy G, Saadeddin Anas, Revert Fernando, Blasco Raül, Navarro Carmen, Burks Deborah, Saus Juan, ;2011;The Journal of biological chemistry;286;35030-43; 21832087
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredyes
Immunocompromisedno

Information from EMMA

Archiving centreCNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain
Animals used for archivinghomozygous unknown males, homozygous unknown females
Stage of embryos2-cell

Disease and phenotype information

IMPC phenotypes (gene matching)
  • preweaning lethality, incomplete penetrance / IMPC
  • decreased mean corpuscular hemoglobin / IMPC
MGI phenotypes (gene matching)
  • abnormal heart morphology / MGI
  • thin ventricular wall / MGI
  • double outlet right ventricle / MGI
  • decreased cell proliferation / MGI
  • abnormal muscle development / MGI
  • abnormal forebrain morphology / MGI
  • abnormal cardiovascular system physiology / MGI
  • decreased embryo size / MGI
  • abnormal lipid homeostasis / MGI
  • abnormal nasal cavity morphology / MGI
  • abnormal semicircular canal morphology / MGI
  • persistent truncus arteriosis / MGI
  • absent tibia / MGI
  • no phenotypic analysis / MGI
  • aphakia / MGI
  • fetal growth retardation / MGI
  • abnormal optic cup morphology / MGI
  • abnormal vertebral arch morphology / MGI
  • fusion of vertebral bodies / MGI
  • fusion of vertebral arches / MGI
  • decreased cervical vertebrae number / MGI
  • homeostasis/metabolism phenotype / MGI
  • cellular phenotype / MGI
  • reproductive system phenotype / MGI
  • decreased ventricle muscle contractility / MGI
  • abnormal cell physiology / MGI
  • abnormal mitochondrion morphology / MGI
  • abnormal mitochondrial physiology / MGI
  • abnormal cardiac outflow tract development / MGI
  • increased heart ventricle size / MGI
  • abnormal cervical rib / MGI
  • abnormal endoplasmic reticulum morphology / MGI
  • abnormal cardiac jelly morphology / MGI
  • perimembraneous ventricular septal defect / MGI
  • muscular ventricular septal defect / MGI
  • abnormal pectinate muscle morphology / MGI
  • persistent right dorsal aorta / MGI
  • embryonic lethality during organogenesis, complete penetrance / MGI
  • abnormal umbilical vein topology / MGI
  • abnormal vertebral artery topology / MGI
  • heterochrony / MGI
  • persistent trigeminal artery / MGI

Literature references

  • Goodpasture antigen-binding protein (GPBP) directs myofibril formation: identification of intracellular downstream effector 130-kDa GPBP-interacting protein (GIP130).;Revert-Ros Francisco, López-Pascual Ernesto, Granero-Moltó Froilán, Macías Jesús, Breyer Richard, Zent Roy, Hudson Billy G, Saadeddin Anas, Revert Fernando, Blasco Raül, Navarro Carmen, Burks Deborah, Saus Juan, ;2011;The Journal of biological chemistry;286;35030-43; 21832087

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).